TP53 and breast cancer: p53 overexpression in breast cancer assessed by IHC is, rather over simplistically, assumed to act as a surrogate for TP53 mutations and is associated with higher tumour grade and responsiveness to radiotherapy, chemotherapy and endocrine therapy (Thompson and Lane, 2010).